Home Biosimilar Antibodies Others Others Refanezumab (Anti-Siglec-4a / MAG)
For research use only. Not for use in humans.

Refanezumab (Anti-Siglec-4a / MAG)

Synonyms: MAG,GMA

Refanezumab (Anti-Siglec-4a / MAG) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. MW : 145.5 KD

Refanezumab (Anti-Siglec-4a / MAG)

Quality Control

Batch: A235601 Purity: 99% Protein concentration: 22.066mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Refanezumab (Anti-Siglec-4a / MAG) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. MW : 145.5 KD

Product Details

CAS No. 1233953-61-1
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07392229 RECRUITING Drug: Zanubrutinib Oral Capsule Anti-MAG IgM-associated Demyelinating Polyneuropathy Azienda Ospedaliera di Padova 2026-03-24 PHASE2
NCT07663279 NOT_YET_RECRUITING End Stage Renal Disease Elisabethinen Hospital 2026-10
NCT05986578 RECRUITING Cocaine Use Disorder The University of Texas Health Science Center, Houston 2024-11-08
NCT07106229 NOT_YET_RECRUITING Knee Osteoarthristis Magellan Stem Cells 2025-11 PHASE3
NCT07528612 NOT_YET_RECRUITING Drug: Magnesium group|Drug: Placebo Postoperative Pain; Quality of Recovery (QoR-15); Pain Prediction; Magnesium Sulfate; Pain Interference; Self-Efficacy Region Halland 2026-04-02 PHASE2
NCT05389787 RECRUITING Schizophrenia; Cerebellar Function; Condition Northwell Health 2022-08-18

(data from https://clinicaltrials.gov, updated on 2026-08-28)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.